权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer

新型单向 Pd-103 CivaSheet 用于肺癌的临床评估

基本信息

批准号：
10250609
负责人：
Kristy Perez
金额：
$ 0.06万
依托单位：
CIVATECH ONCOLOGY, INC.
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-13 至 2021-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10250609
关键词：
Absorbable Implants Acute Applications Grants Brachytherapy Cancer Patient Chest Chest wall structure Clinical Clinical Trials Data Devices Disease Dose Dose-Limiting Effectiveness Encapsulated Excision External Beam Radiation Therapy Gold Grant Heart Implant Injury Institution Instruction Lobe Lobectomy Localized Malignant Neoplasm Location Lung Malignant Neoplasms Malignant neoplasm of lung Mediastinum Membrane Methods Mission Monitor Movement National Comprehensive Cancer Network New York City Oncology Operative Surgical Procedures Organ Outcome Overdose Pain Palladium 103 Patients Phase Polymers Positioning Attribute Procedures Protocols documentation Quality of life Radiation Radiation Dose Unit Radiation Oncologist Radiation Tolerance Radiation therapy Readiness Recommendation Recurrence Reporting Research Personnel Resected Risk Safety Side Site Source Statistical Data Interpretation Structure Surgeon Surgical margins Techniques Testing Therapeutic Effect Time TimeLine Tissues Toxic effect Training Tumor Tissue Vertebral column Work X-Ray Computed Tomography appropriate dose arm cancer therapy clinical research site cohort cost effective dosimetry follow-up implantable device implantation improved in vivo infection risk lung lobe minimally invasive mortality novel patient population primary endpoint recruit research clinical testing side effect standard of care tumor

项目摘要

CivaTech Oncology’s mission is to provide improved radiation therapy directly to localized tumors. The Company has developed a novel, polymer-encapsulated, membrane-like radiation source that emits radiation on only one side of the device – the CivaSheet. This directional source is compatible with open and minimally invasive surgical techniques and has FDA clearance to be used as primary or combined cancer therapy. The CivaSheet is a partially bio-absorbable implant that can be applied at the time of the initial surgery. The CivaSheet decreases the time between surgery and radiation therapy, which is a benefit to the patient. Additionally, the CivaSheet can shield healthy tissues while irradiating the diseased tissue or tumor margin. This shielding enables the CivaSheet to be implanted close to radiosensitive structures without overdosing them – a potential advantage for cancers in the thorax. In Phase I, CivaTech Oncology will confirm the CivaSheet does not move after implantation and that excellent dosimetry can be achieved. The CivaSheet will be implanted during lung lobe segmentation or wedge resection – a standard of care procedure for lung cancer patients who cannot tolerate full lobectomy. The CivaSheet will benefit these patients by delivering radiation therapy at the time of initial surgery to minimize delay in the treatment. For lung cancer patients complete lobectomy is preferred for patients who can tolerate it. For those who cannot, radiation to the surgical margin is a potential benefit. In Phase I, the safety of CivaSheet and general recommendations for its use in this patient population will be assessed. Changes to the surgical implant technique will be assessed as well. The Phase II will consist of two concurrent clinical trials exploring the use of the CivaSheet as boost radiation therapy in lung cancer patients. The rate of local recurrence in patients implanted with CivaSheet will be compared to the current rate of 20%. Additionally, the quality of life, pain, and mortality in each patient will be monitored. CivaSheet will reduce the radiation delivered to adjacent mediastinum and therefore should result in fewer side effects. Additionally, it will provide a conformal dose, reduce the risk for infection, and possibly reduce treatment related side effects. CivaSheet is a truly unique brachytherapy device that has the potential to become the first line of defense for localized cancer. CivaTech Oncology is committed to making the CivaSheet available to cancer patients in multiple indications.

CivaTech Oncology的使命是提供直接针对局部的改进放射治疗